Reports 1H net sales DKK 154.94B vs. DKK 133.41B last year. Reports 1H operating profit DKK 72.24B vs. DKK 57.78B last year. Lars Fruergaard Jorgensen, president and CEO: “While delivering 18% sales growth in the first half of 2025, we have lowered our full-year outlook due to lower growth expectations for our GLP-1 treatments in the second half of 2025. As a result, we are taking measures to sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth. With more than one billion people living with obesity globally, including more than 100 million living in the US, and only a few million on treatment, I am confident that under Mike Doustdar’s leadership, Novo Nordisk (NVO) will maximise the significant growth opportunities, supported by a strong product portfolio and future pipeline”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk Reports Strong H1 2025 Growth but Lowers Full-Year Outlook
- Novo Nordisk Shares Down 44% YTD as Wegovy Sales Jump 67%, But Guidance Stays Lower
- Novo Nordisk downgraded to Neutral from Buy at UBS
- Novo Nordisk Faces Legal Storm Over Misleading Projections
- Novo Nordisk Receives Unsolicited Mini-Tender Offer from TRC Capital